Ap­proved COVID-19 vac­cine by April?

MANILA — A vac­cine against the coronaviru­s dis­ease may be ap­proved by April 2021, the best case sce­nario, the coun­try’s Food and Drug Ad­min­is­tra­tion said Fri­day.

The Freeman - - Nation - Philstar.com

“The best case sce­nario, if clin­i­cal tri­als are com­pleted by De­cem­ber or Jan­uary and a com­pany would file with FDA an ap­pli­ca­tion then that’s pos­si­ble by April 2021 that we will have an ap­proved vac­cine,” FDA Direc­tor-Gen­eral Eric Domingo said in a fo­rum.

“Best case sce­nario ‘yun. ‘Yung three to six months (clin­i­cal tri­als) magig­ing three months and they will com­plete all of their anal­y­sis and sub­mit im­me­di­ately to FDA,” he added. (That is the best case sce­nario. It means the clin­i­cal tri­als which will last three to six months will just be three months and they will com­plete all of their anal­y­sis and sub­mit im­me­di­ately to FDA.)

Depart­ment of Sci­ence and Tech­nol­ogy Sec­re­tary For­tu­nato dela Peña said the time­frame of three to six months is the pro­jec­tion of ex­perts.

“You can al­ready es­ti­mate the very early fore­cast we have of sec­ond quar­ter of 2021 is still the best fore­cast that we can give,” Dela Peña said.

17 vac­cine de­vel­op­ers Dela Peña said that Philip­pines is in talks with 17 vac­cine de­vel­op­ers from dif­fer­ent coun­tries as it seeks to source a COVID-19 vac­cine that will help end the coun­try’s coronaviru­s out­break.

Six for­eign phar­ma­ceu­ti­cal com­pa­nies al­ready signed con­fi­den­tial­ity dis­clo­sure agree­ments (CDA) with the govern­ment. A CDA al­lows clin­i­cal data shar­ing.

Of the six vac­cine mak­ers, Rus­sia’s Ga­ma­leya Re­search In­sti­tute and China’s Si­no­vac ex­pressed in­tent to hold clin­i­cal tri­als and ven­ture into lo­cal man­u­fac­tur­ing in the Philip­pines. China’s Sinopharm sig­ni­fied in­ter­est to sup­ply their prod­ucts to the coun­try.

Meanwhile, China’s ZFSW, Tai­wan’s Adim­mune and Aus­tralia’s Univer­sity of Queens­land are dis­cussing with Philip­pine au­thor­i­ties for pos­si­ble clin­i­cal tri­als.

Can­di­date vac­cines that will be in­cluded in the World Health Or­ga­ni­za­tion’s sol­i­dar­ity tri­als will be tested in eight trial

zones across the coun­try and will in­volve 13 health fa­cil­i­ties.

Ac­cord­ing to IATF’s Res­o­lu­tion 68, the WHO sol­i­dar­ity vac­cine trial will be pri­or­i­tized in the as­sign­ment of trial zones. It also said that vac­cine re­cip­i­ents un­der the sol­i­dar­ity trial will be re­cruited from barangays with high­est

COVID-19 cases.

The Philip­pines has 296,775 con­firmed COVID-19 in­fec­tions, with 5,127 deaths as of Thurs­day. —

AGENCE FRANCE PRESSE

Si­no­vac Biotech vac­cines, one of 11 Chi­nese com­pa­nies ap­proved to carry out clin­i­cal tri­als of po­ten­tial coronaviru­s vac­cines, are dis­played at a press con­fer­ence dur­ing a me­dia tour of a new fac­tory built to pro­duce Covid-19 coronaviru­s vac­cines.

Newspapers in English

Newspapers from Philippines

© PressReader. All rights reserved.